Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Heart drug study halted early: what we know

NCT ID NCT06005428

Disease control Sponsor: Cardurion Pharmaceuticals, Inc. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early This study
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested an experimental drug called CRD-4730 in people with a rare inherited heart rhythm disorder (CPVT) that can cause dangerous fast heartbeats. Seven adults received two different doses of the drug and a placebo to check safety and how the body processes it. The study was stopped early, so results are limited.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

7 people

The number who actually took part.

Started

Nov 2023

Finished

May 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 99 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Males or Females ≥18 years of age, at screening. 2. Confirmed CPVT diagnosis, based on genetic screening for a known RyR2 mutation and a clinical phenotype consistent with CPVT at screening. 3. The participant can perform an EST during which frequent premature ventricular contraction (PVCs) (≥10 per minute), ventricular bigeminy, or higher-grade VA (equivalent to a VA score ≥2) are identified by the investigator. 4. Stable doses of any anti-arrhythmic medication, except amiodarone, for 4 weeks prior to screening. 5. Adhere to all contraceptive criteria. Exclusion Criteria: 1. Clinically significant structural heart disease, diagnosis of heart failure, or clinically significant coronary artery disease. 2. History of a myocardial infarction, cerebrovascular accident, or transient ischemic attack within 3 months of screening. 3. History of malignancy within the past 5 years at screening (except successfully treated basal cell carcinoma or non-metastatic squamous cell carcinoma of the skin or cervical carcinoma in situ). 4. Female participant that is pregnant or lactating/ breastfeeding, or has plans to do so during the study or within 3 months following last dose of study drug. 5. Use of amiodarone with 3 months prior to screening. NOTE: other protocol defined Inclusion/ Exclusion criteria may apply.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Catecholaminergic polymorphic ventricular tachycardia are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

catecholaminergic polymorphic ventricular tachycardia catecholaminergic polymorphic ventricular tachycardia 1 congenital heart disease heart disorder ventricular tachycardia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CPVT1 Heart defects, congenital Heart diseases Ventricular tachycardia

Contacts and locations

Locations

  • Baylor College of Medicine

    Houston, Texas, 77030, United States

  • British Columbia Children's Hospital

    Vancouver, British Columbia, V6H 3N1, Canada

  • Cincinnati Children's Hospital Medical Center

    Cincinnati, Ohio, 45229, United States

  • Cleveland Clinic Children's Hospital

    Cleveland, Ohio, 44195, United States

  • Groupe Hospitalier Bichat Claude Bernard

    Paris, 75018, France

  • Hôpital Louis Pradel

    Bron, 69677, France

  • Hôptal Nord Laennec

    Nantes, Loire-Atlantique, 44805, France

  • IRCCS Pavia Istituti Clinici Scientifici Maugeri Spa Società Benefit

    Pavia, Lombardy, 27100, Italy

  • Stollery Children's Hospital University of Alberta

    Edmonton, Alberta, T6G 2R7, Canada

  • University of British Columbia (UBC) Hospital

    Vancouver, British Columbia, V5Z 1M9, Canada

  • University of Western Ontario

    London, Ontario, N6A 5A5, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.